Klotho Neurosciences, SkyBell mutually terminate Share Exchange Agreement

Klotho Neurosciences (KLTO)announced that on June 13, it entered into a Termination and Release Agreement with SkyBell Technologies, formally ending the Share Exchange Agreement previously executed on March 26. “Terminating this agreement allows us to remain focused and build shareholder value while fully concentrating on our core R&D programs,” said Dr. Joseph Sinkule, CEO of KLTO. “We remain committed to delivering transformative therapies for aging and age-related diseases. We believe that anti-aging gene and biologic therapies can be developed to slow the aging process and ultimately reduce mortality caused by age-related organ failure. We are not far from reaching our strategic milestones toward enabling longer, healthier human lifespans.”